Sprouty 2 as a Prognostic Factor in Breast Cancer
Author Information
Author(s): Faratian Dana, Sims Andrew H., Mullen Peter, Kay Charlene, Um InHwa, Langdon Simon P., Harrison David J.
Primary Institution: University of Edinburgh
Hypothesis
Sprouty 2 may play a role in HER2-therapy resistance and could be an independent prognostic factor in breast cancer.
Conclusion
High levels of Sprouty 2 expression are associated with better survival outcomes in breast cancer patients treated with trastuzumab.
Supporting Evidence
- Low Spry2 expression was linked to higher pathological grade and increased risk of death.
- High Spry2 expression was associated with better prognosis in trastuzumab-treated patients.
- The study found that Spry2 could help stratify patients for trastuzumab therapy.
Takeaway
Sprouty 2 helps doctors understand how well a breast cancer treatment might work, and higher levels of it mean better chances of survival.
Methodology
The study involved a meta-analysis of gene expression data and quantitative immunofluorescence to assess Sprouty 2 levels in breast cancer patients.
Potential Biases
Potential biases due to the retrospective nature of the study and lack of randomization.
Limitations
The study was retrospective and did not include informed consent for tissue samples from deceased patients.
Participant Demographics
Patients were primarily women with breast cancer, treated with trastuzumab.
Statistical Information
P-Value
0.008
Confidence Interval
95% CI 1.22–4.26
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website